Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

British journal of clinical pharmacology - 1 Sept 1999

Aitchison K J, Munro J, Wright P, Smith S, Makoff A J, Sachse C, Sham P C, Murray R M, Collier D A, Kerwin R W

Abstract excerpt

AIMS: To investigate whether or not there is a correlation between failure to respond to typical antipsychotics and CYP2D6 ultrarapid metaboliser status. METHODS: CYP2D6 phenotype (metaboliser status) was assigned following genotyping for gene duplication, as well as for the CYP2D6*3, CYP2D6*4, and CYP2D6*5 null alleles in 235 treatment-refractory patients and 73 nonrefractory patients. RESULTS: Four (1.7%) of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Hydroxylation

Share to Schizophrenia

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 10510151
DOI: 10.1046/j.1365-2125.1999.00006.x
PMCID: PMC2014339

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.PMID 10510151Read ↗

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.Semantic proximity Read ↗

Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication.Semantic proximity Read ↗

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.Semantic proximity Read ↗

Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?Semantic proximity Read ↗

Is pharmacogenetic CYP2D6 testing useful?Semantic proximity Read ↗

Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.Semantic proximity Read ↗

CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.Semantic proximity Read ↗

[Pharmacoresistance to psychotropic drugs in children and adolescents: Pharmacogenetic anomalies of cytochrome P450 2D6].Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.Semantic proximity Read ↗

Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.Semantic proximity Read ↗

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.